Oragenics (OGEN) Competitors $1.08 +0.02 (+1.89%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.08 0.00 (0.00%) As of 09/5/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OGEN vs. HOTH, LSB, SYBX, AIMD, LEXX, EDSA, CYCC, PULM, IBIO, and MTVAShould you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include Hoth Therapeutics (HOTH), LakeShore Biopharma (LSB), Synlogic (SYBX), Ainos (AIMD), Lexaria Bioscience (LEXX), Edesa Biotech (EDSA), Cyclacel Pharmaceuticals (CYCC), Pulmatrix (PULM), iBio (IBIO), and MetaVia (MTVA). These companies are all part of the "pharmaceutical products" industry. Oragenics vs. Its Competitors Hoth Therapeutics LakeShore Biopharma Synlogic Ainos Lexaria Bioscience Edesa Biotech Cyclacel Pharmaceuticals Pulmatrix iBio MetaVia Oragenics (NYSE:OGEN) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Do analysts prefer OGEN or HOTH? Hoth Therapeutics has a consensus price target of $4.00, indicating a potential upside of 200.75%. Given Hoth Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Hoth Therapeutics is more favorable than Oragenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oragenics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, OGEN or HOTH? Oragenics has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Hoth Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Which has higher earnings & valuation, OGEN or HOTH? Hoth Therapeutics is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOragenicsN/AN/A-$20.66M-$21.42-0.05Hoth TherapeuticsN/AN/A-$8.19M-$1.07-1.24 Is OGEN or HOTH more profitable? Hoth Therapeutics' return on equity of -114.32% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets OragenicsN/A -2,087.95% -486.56% Hoth Therapeutics N/A -114.32%-105.92% Does the media favor OGEN or HOTH? In the previous week, Hoth Therapeutics had 4 more articles in the media than Oragenics. MarketBeat recorded 6 mentions for Hoth Therapeutics and 2 mentions for Oragenics. Oragenics' average media sentiment score of 0.50 beat Hoth Therapeutics' score of -0.51 indicating that Oragenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oragenics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hoth Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Negative Do insiders & institutionals believe in OGEN or HOTH? 18.7% of Oragenics shares are held by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are held by institutional investors. 4.9% of Oragenics shares are held by insiders. Comparatively, 6.9% of Hoth Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryHoth Therapeutics beats Oragenics on 9 of the 13 factors compared between the two stocks. Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGEN vs. The Competition Export to ExcelMetricOragenicsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$4.46M$952.75M$5.83B$21.33BDividend YieldN/A4.84%6.70%3.49%P/E Ratio-0.151.1876.2229.64Price / SalesN/A26.54530.7267.50Price / CashN/A19.5636.9925.18Price / Book1.776.7311.484.55Net Income-$20.66M-$3.82M$3.29B$999.70M7 Day Performance4.85%0.54%1.28%0.58%1 Month Performance-16.92%12.76%8.56%5.67%1 Year Performance-93.01%30.05%61.19%18.25% Oragenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGENOragenics0.678 of 5 stars$1.08+1.9%N/A-93.0%$4.46MN/A-0.155Short Interest ↓HOTHHoth Therapeutics2.5007 of 5 stars$1.33+3.9%$4.00+200.8%+25.5%$17.64MN/A-1.244LSBLakeShore Biopharma1.4739 of 5 stars$0.85+3.0%N/A-81.0%$17.57M$85.67M0.00773Positive NewsShort Interest ↓Gap DownSYBXSynlogicN/A$1.49+2.1%N/A+0.7%$17.43MN/A-18.6380AIMDAinos0.4098 of 5 stars$3.74+2.2%N/A+27.2%$17.43M$20K-0.7540News CoverageAnalyst UpgradeShort Interest ↑Gap DownLEXXLexaria Bioscience2.9211 of 5 stars$0.89+0.1%$4.00+351.0%-67.1%$17.35M$460K-1.327Short Interest ↑EDSAEdesa Biotech1.2664 of 5 stars$2.45+4.7%$5.00+104.1%-42.9%$17.25MN/A-1.8620CYCCCyclacel Pharmaceuticals1.2663 of 5 stars$7.69flatN/A-97.2%$17.23M$40K-0.0114Positive NewsAnalyst DowngradeShort Interest ↓PULMPulmatrix0.6859 of 5 stars$4.65-2.3%N/A+143.5%$16.97M$369K-2.1420Short Interest ↓IBIOiBio1.9468 of 5 stars$0.86+5.9%$5.00+482.2%-53.1%$16.88M$375K0.00100News CoverageMTVAMetaVia2.517 of 5 stars$0.67+5.1%$7.50+1,020.2%N/A$16.20MN/A0.008Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Hoth Therapeutics Competitors LakeShore Biopharma Competitors Synlogic Competitors Ainos Competitors Lexaria Bioscience Competitors Edesa Biotech Competitors Cyclacel Pharmaceuticals Competitors Pulmatrix Competitors iBio Competitors MetaVia Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGEN) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
